Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study

Keyphrases

• Tyrosine Kinase Inhibitor 100%
• Antiangiogenic 100%
• Cardiovascular Toxicity 100%
• Pharmacovigilance 100%
• Vascular Endothelial Growth Factor Receptor Inhibitor 100%
• Reporting Odds Ratio 90%
• Cardiovascular Adverse Events 63%
• Aortic Dissection 45%
• Pericardial Disease 45%
• Hypertension 27%
• Sunitinib 27%
• Lenvatinib 27%
• Marketing Information 18%
• Nonmalignant 18%
• Renal Cell Carcinoma 18%
• Cabozantinib 18%
• FDA Adverse Event Reporting System (FAERS) 18%
• Postmarketing 18%
• Axitinib 18%
• Pazopanib 18%
• Adverse Event Reporting 18%
• Malignant Pericardial Effusion 18%
• Adverse Event Reporting System Database 18%
• Elevated Blood Pressure 9%
• Solid Tumors 9%
• Heart Failure 9%
• Venous Thromboembolism 9%
• Cardiomyopathy 9%
• Therapeutic Potential 9%
• U.S. Food 9%
• Information Component 9%
• Surveillance Data 9%
• Credibility Intervals 9%
• Tyrosine Kinase Inhibitor Treatment 9%
• Safety Report 9%
• Post-marketing Surveillance 9%
• Disproportionality Analysis 9%
• Reporting Patterns 9%
• Adverse Event Reporting System 9%

Medicine and Dentistry

• Tyrosine-Kinase Inhibitor 100%
• Antiangiogenic 100%
• Cardiovascular Toxicity 100%
• Pharmacovigilance 100%
• Adverse Event 91%
• Protein Tyrosine Kinase 91%
• Vasculotropin Receptor 91%
• Odds Ratio 83%
• Cardiovascular System 58%
• Aortic Dissection 41%
• Pericardial Disorder 41%
• Sunitinib 25%
• Lenvatinib 25%
• Pericardial Fluid 16%
• Clear Cell Renal Cell Carcinoma 16%
• Cabozantinib 16%
• Pazopanib 16%
• Axitinib 16%
• Elevated Blood Pressure 8%
• Clinician 8%
• Solid Malignant Neoplasm 8%
• Heart Failure 8%
• Bleeding 8%
• Venous Thromboembolism 8%
• Cardiomyopathy 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Tyrosine Kinase Inhibitor 100%
• Antiangiogenic 100%
• Cardiovascular Toxicity 100%
• Pharmacovigilance 100%
• Adverse Event 91%
• Protein Tyrosine Kinase 91%
• Vasculotropin Receptor 91%
• Aortic Dissection 41%
• Pericardial Disease 33%
• Sunitinib 25%
• Lenvatinib 25%
• Renal Cell Carcinoma 16%
• Pericardial Effusion 16%
• Cabozantinib 16%
• Axitinib 16%
• Pazopanib 16%
• Disease 8%
• Bleeding 8%
• Elevated Blood Pressure 8%
• Heart Failure 8%
• Venous Thromboembolism 8%
• Solid Malignant Neoplasm 8%
• Cardiomyopathy 8%
• Postmarketing Surveillance 8%
• Disproportionality Analysis 8%